Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers Timothy A. Yap , Rebecca Kristeleit , Vasiliki Michalarea , Stephen J. Pettitt , Joline S.J. Lim , Suzanne Carreira , Desamparados Roda , Rowan Miller , Ruth Riisnaes , Susana Miranda , Ines Figueiredo , Daniel Nava Rodrigues , Sarah Ward , Ruth Matthews , Mona Parmar , Alison Turner , Nina Tunariu , Neha Chopra , Heidrun Gevensleben , Nicholas C. Turner , Ruth Ruddle , Florence I. Raynaud , Shaun Decordova , Karen E. Swales , Laura Finneran , Emma Hall , Paul Rugman , Justin P.O. Lindemann , Andrew Foxley , Christopher J. Lord , Udai Banerji , Ruth Plummer , Bristi Basu , Juanita S. Lopez , Yvette Drew , Johann S. de Bono crossref（2023）
摘要
Supplementary Tables 1-7; Supplementary Figures 1-2; Supplementary Methods
更多 查看译文
AI 理解论文
溯源树
样例
